Literature DB >> 9315461

Aggressive cholesterol management: role of the lipid nurse specialist.

L A Cofer1.   

Abstract

There are millions of people with coronary heart disease and tens of millions more who are at risk. Research reveals that aggressive cholesterol management, especially in patients with known coronary heart disease, reduces the incidence of clinical cardiac events and improves survival rates. A review of the literature reveals disturbing evidence that patients with dyslipidemia are not being treated according to the National Cholesterol Education Program guidelines. The need for lipid nurse specialists is real and growing; the challenge of managing care for patients with dyslipidemia is tremendous. Because the role of the lipid nurse specialist is relatively new, it is described in detail in this article. Nurses who desire to fight heart disease aggressively will find this area of nursing practice interesting, challenging, and rewarding. Nurses who facilitate the implementation of the National Cholesterol Education Program guidelines to the large numbers of patients with dyslipidemia offer a valuable public health service.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315461     DOI: 10.1016/s0147-9563(97)90019-4

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  2 in total

1.  Guidelines for the management of hepatitis C in general practice: a semi-qualitative interview survey of GPs' views regarding content and implementation.

Authors:  W Cullen; M O'Leary; D Langton; J Stanley; Y Kelly; G Bury
Journal:  Ir J Med Sci       Date:  2005 Jul-Sep       Impact factor: 1.568

2.  COACH trial: a randomized controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers: rationale and design.

Authors:  Jerilyn K Allen; Cheryl R Dennison Himmelfarb; Sarah L Szanton; Lee Bone; Martha N Hill; David M Levine
Journal:  Contemp Clin Trials       Date:  2011-01-15       Impact factor: 2.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.